News
VVOS
0.3433
+12.45%
0.0380
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Benzinga · 1d ago
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
*Vivos Therapeutics 2Q Loss/Shr 31c >VVOS
Dow Jones · 1d ago
*Vivos Therapeutics 2Q Rev $5.15M >VVOS
Dow Jones · 1d ago
Press Release: Vivos Therapeutics Reports Second -2-
Dow Jones · 1d ago
Press Release: Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Dow Jones · 1d ago
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Benzinga · 1d ago
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
Barchart · 2d ago
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 3d ago
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices
TipRanks · 4d ago
Vivos Therapeutics expands strategic engagement with Greenway Health
TipRanks · 5d ago
Vivos Therapeutics Expands Greenway Health AI Partnership, Could Create Up To $9M In Potential Annual Value
Benzinga · 5d ago
Weekly Report: what happened at VVOS last week (0803-0807)?
Weekly Report · 6d ago
Zoetis (ZTS) Surpasses Q2 Earnings Estimates
NASDAQ · 08/06 12:20
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 08/05 17:05
Vivos Therapeutics issued new U.S. patent for Vivos CARE devices
TipRanks · 08/05 14:01
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 08/05 12:05
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 08/05 08:57
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/04 21:06
Vivos Therapeutics Has Been Granted U.S. Patent Number 12,697,190 Titled "VIBRATIONAL ORAL APPLIANCE WITH MANDIBULAR ADVANCEMENTS"
Benzinga · 08/04 19:58
More
Webull provides a variety of real-time VVOS stock news. You can receive the latest news about Vivos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.